Entities / Company
Revolution Medicines (United States).
company in Redwood City, United States
- Reports this week
- 0
- Active events
- 0
- Connections
- 43
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Earlier this month
One to three months ago
Gone quiet
No new reports in 90+ days-
Revolution Medicines is advancing trials for various cancers, including metastatic PDAC, NSCLC, and CRC, leveraging RAS inhibitors and targeted therapies, alongside benefits from tariffs and analyst upgrades.Some support3 reports1 development inside
-
Revolution Medicines and Summit Therapeutics announced a collaboration on August 19, 2025, to evaluate combination therapies.Some support3 reports1 development inside
-
Revolution Medicines and Summit Therapeutics are collaborating to evaluate combination therapies using RAS inhibitors and ivonescimab for targeted cancer treatment.Speculative1 report
-
Revolution Medicines and Iambic Therapeutics announced a collaboration to develop targeted therapies for RAS-addicted cancers using AI discovery tools.Some support1 report
-
Revolution Medicines announced that Mark A. Goldsmith, in his role as CEO and Chairman, stated on July 23, 2025, that encouraging clinical data demonstrated therapeutic potential for elironrasib.Some support1 report
-
Jan Smith was appointed chief scientific officer of Revolution Medicines on July 25, 2025.Some support1 report
-
Revolution Medicines develops targeted therapies for RAS-addicted cancers and uses LinkedIn for corporate communication.Well supported4 reports
-
Revolution Medicines received Breakthrough Therapy Designation and entered into a major funding agreement, while activating international clinical trials in Europe and Japan.Some support4 reports
-
Revolution Medicines submitted data for elironrasib, a clinical-stage drug, for review by the FDA for treating Non-Small Cell Lung Cancer.Some support7 reports
-
Wells Fargo initiated coverage with a Buy rating for Revolution Medicines on August 29, 2025.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Revolution Medicines (United States) this week
News at the entities that move Revolution Medicines (United States) most-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves Revolution Medicines (United States)
-
LinkedIn OperationalBoth LinkedIn and Google are currently being utilized as platforms for news distribution.Moves Revolution Medicines (United States)
Connections
The 6 strongest of 43, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Ras Structural
Revolution Medicines develops targeted therapies and inhibitors specifically aimed at the Ras protein/gene.
-
Summit Therapeutics Operational
The companies are engaged in a clinical collaboration to evaluate drug combinations for cancer treatment.
-
Mark A. Goldsmith Structural
Mark A. Goldsmith holds the formal role of CEO and Chairman at Revolution Medicines.
-
Tango Therapeutics (United States) Structural
Tango Therapeutics utilizes RAS(ON) inhibitors developed by Revolution Medicines in its clinical trials.
-
FDA Structural
The FDA granted Breakthrough Therapy Designation to Revolution Medicines' drug daraxonrasib.
-
LinkedIn Operational
Revolution Medicines utilizes LinkedIn as a platform for corporate and investor communication.
History
Events by the month they beganJune 2026
12 events- Analysts have set price targets for Revolution Medicines (Q107518109), indicating potential stock upside.
- daraxonrasib received Breakthrough Therapy Designation from the FDA for metastatic pancreatic ductal adenocarcinoma.
- Revolution Medicines is advancing trials for various cancers, including metastatic PDAC, NSCLC, and CRC, leveraging RAS inhibitors and targeted therapies, alongside benefits from tariffs and analyst upgrades.
- Revolution Medicines and Summit Therapeutics announced a collaboration on August 19, 2025, to evaluate combination therapies.
- Revolution Medicines and Summit Therapeutics are collaborating to evaluate combination therapies using RAS inhibitors and ivonescimab for targeted cancer treatment.
- Revolution Medicines and Iambic Therapeutics announced a collaboration to develop targeted therapies for RAS-addicted cancers using AI discovery tools.
- Revolution Medicines announced that Mark A. Goldsmith, in his role as CEO and Chairman, stated on July 23, 2025, that encouraging clinical data demonstrated therapeutic potential for elironrasib.
- Jan Smith was appointed chief scientific officer of Revolution Medicines on July 25, 2025.
- Revolution Medicines develops targeted therapies for RAS-addicted cancers and uses LinkedIn for corporate communication.
- Revolution Medicines received Breakthrough Therapy Designation and entered into a major funding agreement, while activating international clinical trials in Europe and Japan.
- Revolution Medicines submitted data for elironrasib, a clinical-stage drug, for review by the FDA for treating Non-Small Cell Lung Cancer.
- Wells Fargo initiated coverage with a Buy rating for Revolution Medicines on August 29, 2025.